Hosted on MSN4h
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy RecommendationFintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback